Abstract:IMPORTANCE This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). OBJECTIVE To assess the efficacy and safety/tolerability of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced sq-NSCLC. DESIGN, SETTING, AND PARTICIPANTS This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. The data cutoff for these analyses was December 6, 2019; data extraction occurred on January 7, 2020. INTERVENTIONS Patients were randomized (1:1:1) to receive 1 of the following regimens intravenously on a 21-day cycle: tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m(2), day 1) and carboplatin (area under the concentration of 5, day 1) (arm A); tislelizumab plus nab-paclitaxel (100 mg/m(2), days 1, 8, and 15) and carboplatin (arm B); and paclitaxel and carboplatin (arm C). Patients were stratified by disease stage and tumor programmed cell death 1 ligand 1 (PD-L1) expression (<1% vs 1%-49% vs >= 50%). MAIN OUTCOMES AND MEASURES The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC). Secondary end points included overall survival, investigator-assessed (INV) PFS, IRC-assessed objective response rate (ORR), and IRC-assessed duration of response, as well as the incidence and severity of adverse events (AEs). RESULTS Overall, 355 patients (median [range] age, 62 [34-74] years; 330 men [91.7%]) with sq-NSCLC received treatment. After a median study follow-up of 8.6 months (95% CI, 8.1-9.0 months), IRC-assessed PFS was significantly improved with tislelizumab plus chemotherapy (arm A, 7.6 months; arm B, 7.6 months) vs chemotherapy alone (arm C, 5.5 months; hazard ratios were 0.524 (95% CI, 0.370-0.742; P < .001 [A vs C]) and 0.478 (95% CI, 0.336-0.679; P < .001 [B vs C]). Higher IRC-assessed ORR and longer IRC-assessed duration of response were observed in arms A (72.5%; 8.2 months) and B (74.8%; 8.6 months) vs C (49.6%; 4.2 months). No association was observed between PD-L1 expression and IRC-assessed PFS or ORR. Discontinuation of any treatment because of AEs was reported in 15 (12.5%; arm A), 35 (29.7%; arm B), and 18 (15.4%; arm C) patients. In each arm, the most common grade of 3 or greater AE was decreased neutrophil levels, which aligned with known chemotherapy toxic effects. Six treatment-related AEs leading to death occurred; however, no deaths were solely attributed to tislelizumab. CONCLUSIONS AND RELEVANCE In this phase 3 randomized clinical trial, adding tislelizumab to chemotherapy was associated with significantly prolonged IRC-assessed PFS, higher IRC-assessed ORRs, and a manageable safety/tolerability profile in patients with advanced sq-NSCLC, regardless of PD-L1 expression.

100P Phase II Trial of Tislelizumab Plus Bevacizumab and Chemotherapy As the First-Line Therapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Updated Efficacy and Safety Results

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

Tislelizumab in Combination with Chemotherapy in Chinese Patients with Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer: Results from One Cohort of an Ongoing Phase 2 Study.

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer

1264P Updated Analysis of Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC)

Toripalimab Combined with Bevacizumab and Chemotherapy As First-Line Treatment for Refractory, Recurrent or Metastatic Cervical Cancer: a Single-Arm, Open-Label, Phase II Trial

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

Toripalimab Combined with Bevacizumab Plus Chemotherapy As First-Line Treatment for Refractory Recurrent or Metastatic Cervical Cancer: a Single-Arm, Open-Label, Phase II Study (JS001-ISS-CO214).

Tislelizumab in Combination with Chemotherapy for the Treatment of Chinese Patients (pts) with Esophageal Squamous Cell Carcinoma (ESCC): Results from One Cohort of an Ongoing Phase 2 Study.

Preoperative (neoadjuvant) Therapy with Tislelizumab for Locally Advanced Colorectal Cancer with High Microsatellite Instability or Deficient Mismatch Repair: an Open-Label, Single-Arm, Multicenter Phase II Study.

OA03.04 Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.

Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).

743MO Efficacy and Safety of QL1706 Plus Paclitaxel and Cisplatin/carboplatin +/- Bevacizumab (bev) As 1L Treatment in Recurrent or Metastatic Cervical Cancer (r/mcc): A Single-Arm, Multicenter Phase II Study

P2.04-29 Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.

Phase II Study of Tislelizumab Combined with Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer.

RATIONALE-309: Updated progresssion -free survival from a phase 3 double-blind trail of tislelizumab versus placebo, plus chemotherapy, as first -line treatment for recurrent/metastatic nasopharyngeal cancer.

Tislelizumab, an Investigational Anti-Pd-1 Antibody, Combined with Chemotherapy As First-Line Treatment for Lung Cancer in Chinese Patients.